AB&B BIO-TECH-B (02627) announced that the National Medical Products Administration (NMPA) of China has approved the new drug application for the Group's trivalent influenza virus subunit vaccine intended for all age groups. As of the date of this announcement, this vaccine has become the first and only fully-population, full-dose trivalent influenza virus subunit vaccine approved for marketing in China. The product represents a significant upgrade over traditional split-virus vaccines, offering advantages such as comprehensive protection, high purity of component antigens, and a lower risk of adverse reactions.